Intra-Cellular Therapies, Inc.
Clinical trials sponsored by Intra-Cellular Therapies, Inc., explained in plain language.
Now part of
Johnson & Johnson
JNJ
NYSE
Biopharma developing CNS treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill may ease anxiety when current meds fall short Results expected Mar 2027 (estimated)
- Could a new pill boost antidepressants for Tough-to-Treat depression? Results expected Apr 2027 (estimated)
- Could a new pill ease irritability in kids with autism? Results expected Jun 2027 (estimated)
- Could a new pill tame Autism-Related irritability in kids? Results expected Jun 2027 (estimated)